Genentech

**About Us** Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology since we were founded in 1976. Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. Our transformational discoveries include the first targeted antibody for cancer and the first medicine for primary progressive multiple sclerosis. The life-changing scientific breakthroughs Genentech has delivered over the last five decades stand as a testament to this patient-first philosophy. However, we are not resting on our legacy; we are building on it. Genentech is now leading the next revolution in human health, ensuring we remain at the forefront of scientific progress for the next 50 years. Today, we are pioneering the integration of AI and data science into every facet of drug discovery and patient care. Our longevity is a direct result of fostering an entrepreneurial culture where intellectual curiosity, cross-disciplinary collaboration, and the courage to take scientific risks are not just encouraged—they are mandated. This unique environment ensures that the innovation pipeline remains robust and disruptive. We believe a great people experience is critical for revolutionizing healthcare and living Our Promise. That’s why we’re committed to cultivating an environment where people feel valued, included and able to thrive.